NASDAQ:VIE Viela Bio (VIE) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free VIE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$53.01▼$53.0150-Day Range$52.92▼$53.2052-Week Range$25.02▼$65.00VolumeN/AAverage Volume1.07 million shsMarket Capitalization$2.91 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Viela Bio alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Viela Bio Stock (NASDAQ:VIE)Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.Read More Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide VIE Stock News HeadlinesApril 16, 2024 | finance.yahoo.comFcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsightJanuary 29, 2024 | benzinga.comArriVent Wows Investors With Promising China-Developed Lung Cancer TreatmentApril 26, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. January 27, 2024 | bizjournals.comArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024January 9, 2024 | seekingalpha.comArriVent Biopharma Seeks $100 Million IPO For Lung Cancer DrugJanuary 5, 2024 | marketwatch.comArriVent BioPharma Files For IPODecember 6, 2023 | finance.yahoo.comMyasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%November 17, 2023 | benzinga.comGlobal CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key PlayersApril 26, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. November 9, 2023 | uk.finance.yahoo.comGlobal CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of TherapiesNovember 3, 2023 | finance.yahoo.comGlobal CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in ImmunotherapyOctober 25, 2023 | bizjournals.comAmgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for nowOctober 23, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerSeptember 20, 2023 | usatoday.comInside 'Elon Musk': Wild details from revealing Walter Isaacson biographyJuly 26, 2023 | nypost.comI’m an AI influencer: Followers crave my sexy snaps — but I don’t existMay 8, 2023 | marketwatch.com2023 Cutaneous Lupus Erythematosus (CLE) Treatment Market: Latest Technology Innovations and Comprehensive Growth Insights by 2031May 5, 2023 | marketwatch.comCutaneous Lupus Erythematosus (CLE) Treatment Market: Opportunities for Industry Expansion in 2030May 5, 2023 | marketwatch.com8-K: Horizon Therapeutics Public Ltd CoMarch 27, 2023 | bizjournals.comArriVent Biopharma raises $155M in one of largest local funding rounds of 2023March 9, 2023 | marketwatch.comCutaneous Lupus Erythematosus (CLE) Treatment Market Application, Product, Sales and Forecast 2023-2028February 10, 2023 | marketwatch.comExploring the Challenges and Opportunities in the Cutaneous Lupus Erythematosus (CLE) Treatment Market (2023-2028)January 20, 2023 | marketwatch.comNeuromyelitis Optica Spectrum Disorder (NMOSD) Market is Set to Grow in forecast period 2029December 13, 2022 | bizjournals.comWith Horizon acquisition, Amgen would enter Montgomery County for the first time. Here’s what we know.December 1, 2022 | bizjournals.comHorizon Therapeutics spells out vision for Rockville R&D hubNovember 16, 2022 | bizjournals.comLife sciences firm MilliporeSigma doubling down on MoCo with $286M investmentNovember 15, 2022 | seekingalpha.comSBI Holdings, Inc. (SBHGF) Q2 2023 Earnings Call TranscriptNovember 2, 2022 | msn.comWhy Horizon Therapeutics' Shares Rose 11.32% on WednesdaySee More Headlines Receive VIE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2021Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:VIE CUSIPN/A CIKN/A Webwww.vielabio.com Phone240 558 0038FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.97% Return on Assets-31.49% Debt Debt-to-Equity RatioN/A Current Ratio19.51 Quick Ratio19.49 Sales & Book Value Annual Sales$50 million Price / Sales58.26 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book7.42Miscellaneous Outstanding Shares54,950,000Free FloatN/AMarket Cap$2.91 billion OptionableNot Optionable Beta0.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Zhengbin Yao (Age 55)Chairman, Pres & CEO Comp: $846.75kMr. Mitchell Chan (Age 40)Chief Financial Officer Comp: $420.34kDr. Jörn Drappa M.D. (Age 56)Ph.D., Chief Medical Officer and Head of R&D Comp: $637.39kMr. James Paul Kastenmayer J.D. (Age 49)Ph.D., Gen. Counsel & Company Sec. Ms. Kate SurdezSr. VP & Head of HRMs. Rachel EttingerSr. Director & Head of ResearchMr. Bill ReesSr. Director & Head of Translational ScienceMr. Ted PhillipsVP & Head of Clinical OperationsMr. Dewei SheSr. Director and Head of Biostatistics, Data Management, & ProgrammingMr. Lee LevinSr. Director & Head of QualityMore ExecutivesKey CompetitorsIDEAYA BiosciencesNASDAQ:IDYAArrowhead PharmaceuticalsNASDAQ:ARWRMoonLake ImmunotherapeuticsNASDAQ:MLTXACADIA PharmaceuticalsNASDAQ:ACADCrinetics PharmaceuticalsNASDAQ:CRNXView All Competitors VIE Stock Analysis - Frequently Asked Questions How were Viela Bio's earnings last quarter? Viela Bio, Inc. (NASDAQ:VIE) posted its earnings results on Sunday, February, 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.10. The firm earned $9.34 million during the quarter, compared to the consensus estimate of $5.10 million. When did Viela Bio IPO? Viela Bio (VIE) raised $150 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager. This page (NASDAQ:VIE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viela Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
